Responses
Regular and young investigator award abstracts
Clinical trials in progress
390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
